CG
KERX

Cutler Group’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Cutler Group’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-700
Closed -$2K – 5293
2018
Q1 		$2K Sell
700
-3,400
-83% -$15.8K ﹤0.01% 3923
2017
Q4 		$19K Buy
4,100
+3,120
+318% +$17.2K ﹤0.01% 2622
2017
Q3 		$6K Buy
980
+244
+33% +$1.75K ﹤0.01% 4313
2017
Q2 		$5K Buy
+736
New +$4.6K ﹤0.01% 4945
2017
Q1 		– Sell
-1,205
Closed -$6.6K – 7681
2016
Q4 		$7K Sell
1,205
-3,709
-75% -$20.3K ﹤0.01% 4671
2016
Q3 		$26K Buy
4,914
+4,400
+856% +$23.7K ﹤0.01% 3179
2016
Q2 		$3K Hold
514
– – ﹤0.01% 5512
2016
Q1 		$2K Sell
514
-5,788
-92% -$23.1K ﹤0.01% 5782
2015
Q4 		$31K Buy
+6,302
New +$29.9K ﹤0.01% 2971

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
PIMJS
PKO Investment Management Joint-Stock Warsaw, Poland $1.38B AUM 59.54% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cutler Group's KERX Position: Q2 2018 in Review

Cutler Group sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2018, closing a stake of 700 shares — an estimated $2K sold.

Cutler Group first reported a position in KERX in Q4 2015 and held it in 9 quarters. The position peaked at $31K in Q4 2015. 132 funds tracked by Wall St. Rank hold KERX as of Q2 2018.

  • Cutler Group reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2018 after selling out during the quarter.
  • Cutler Group sold 700 Keryx Biopharmaceuticals Inc shares in Q2 2018, an estimated $2K.
  • Cutler Group first reported a position in Keryx Biopharmaceuticals Inc in Q4 2015 and held it in 9 quarters.
  • Cutler Group's Keryx Biopharmaceuticals Inc position peaked at $31K in Q4 2015.
  • 132 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2018.

Based on Cutler Group's 13F filing for Q2 2018, filed 10 Aug 2018.